GlassScriptPhysician profile
Jeffrey A Scott
NPI 1417970526
$12,329.50
in general payments reported to CMS, 2019-2025
33 companies · $638 in 2025
The $638 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $438 · 2020: $134 · 2021: $72.01 · 2022: $299 · 2023: $10K · 2024: $586 · 2025: $638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,086 · Food and Beverage: $1,928 · Travel and Lodging: $335 · Education: $36.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,086.00 |
| Food and Beverage | $1,928.29 |
| Travel and Lodging | $335.46 |
| Education | $36.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $9,719.27 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $724.62 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Glaxosmithkline, LLC. | $298.46 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $233.44 | 2022-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $211.48 | 2019-2025 | Ofev, Jascayd |
| Genzyme Corporation | $133.63 | 2019-2025 | |
| Amgen INC. | $83.32 | 2023-2025 | Tezspire |
| Merck Sharp & Dohme LLC | $66.94 | 2019-2024 | Winrevair |
| Bayer Healthcare Pharmaceuticals INC. | $58.63 | 2020-2023 | |
| Eisai INC. | $57.97 | 2024-2025 | |
| Abbvie INC. | $54.57 | 2024-2025 | |
| Janssen Biotech, INC. | $51.96 | 2019-2025 | Rybrevant |
| E.R. Squibb & Sons, L.L.C. | $50.05 | 2023 | Opdivo |
| Karyopharm Therapeutics INC. | $48.97 | 2025 | Xpovio |
| Novartis Pharmaceuticals Corporation | $46.61 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $38.49 | 2022 | |
| Circassia INC. | $36.34 | 2023 | Niox |
| Exelixis INC. | $34.99 | 2023 | Cabometyx |
| United Therapeutics Corporation | $34.82 | 2024 | Tyvaso |
| Insmed, INC. | $33.98 | 2025 | Brinsupri, Arikayce |
| Resmed Corp | $33.71 | 2023-2024 | |
| Pfizer INC. | $31.53 | 2019 | |
| Lilly USA, LLC | $30.54 | 2025 | Zepbound |
| Pharmacyclics LLC, An Abbvie Company | $29.79 | 2023 | Imbruvica |
| Verona Pharma, INC. | $29.53 | 2025 | Ohtuvayre |
| Pulmonx Corporation | $27.21 | 2025 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Mylan Specialty L.P. | $23.99 | 2019 | |
| Genentech USA, INC. | $20.95 | 2019 | |
| Avadel Cns Pharmaceuticals, LLC | $20.86 | 2024 | Lumryz |
| Zoll Respicardia, INC. | $17.38 | 2025 | Remede System |
| Covidien LP | $17.23 | 2020 | |
| Covis Pharma Gmbh | $17.08 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $11.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.